The AML-VACCiN team is excited to announce Accelovance as the latest member of its consortium. Accelovance is a clinical Contract Research Organization (CRO) which is specialized in early phase oncology trials (Phase I-II) and has been chosen to manage the multicentre AML-VACCiN clinical trial. With offices throughout Europe, Accelovance has sufficient critical mass to ensure close proximity of involved staff to each of the AML-VACCiN trial locations. Accelovance has managed over 1000 clinical trials to date, including over a hundred oncology and vaccine product trials, of which several in AML. Thus, Accelovance and its clinical research associates have the required experience with oncology and clinical trials involving triggers to the immune system to understand the special requirements for the AML-VACCiN DCP-001 drug product. All in all, Accelovance is uniquely qualified to manage the AML-VACCiN trial, and is warmly welcomed by the team.